Merck's Dividend Dilemma: Can Growth Sustain Value? Merck's (MRK) stock price has surged 36% year to date, outpacing the Nasdaq Composite's 12% gain over the same period.
This impressive performance raises questions about whether the company can maintain its growth trajectory while keeping dividend yields intact. The acquisition of Terns Pharmaceuticals in May for $6.
7 billion is a key aspect of Merck's success story.